Pharmaceutical company AlzeCure has received a €2.5 million grant from the European Innovation Council (EIC) to advance the Phase II trial of an Alzheimer’s disease treatment. AlzeCure will advance the candidate NeuroRestore ACD856 to a Phase II trial, developed to improve patients’ learning and memory function and affect the course of disease in Alzheimer’s. ACD856 is a so-called Trk-PAM, a […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!